Niagen Bioscience (NAGE) Enterprise Value (2015 - 2026)

Niagen Bioscience (NAGE) has 12 years of Enterprise Value data on file, last reported at -$66.5 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 19.66% year-over-year to -$66.5 million in Q1 2026; TTM through Mar 2026 was -$66.5 million, a 19.66% decrease from a year earlier, with the FY2025 full-year figure at -$64.8 million, down 45.07% from the prior year.
• Enterprise Value for Q1 2026 stood at -$66.5 million, down from -$64.8 million in the prior quarter.
• Over the last five years, Enterprise Value for NAGE reached as high as -$13.3 million in Q3 2022 and fell as low as -$66.5 million in Q1 2026.
• Historically, Enterprise Value has averaged -$36.4 million across 5 years, with a median of -$27.6 million in 2024.
• Across the five-year window, Enterprise Value surged 59.94% in 2022 and slumped 116.87% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$20.4 million in 2022, then sank by 33.68% to -$27.3 million in 2023, then tumbled by 63.44% to -$44.7 million in 2024, then sank by 45.07% to -$64.8 million in 2025, then retreated by 2.72% to -$66.5 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$66.5 million in Q1 2026, -$64.8 million in Q4 2025, and -$64.3 million in Q3 2025.